# Markus Hinder

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8279299/publications.pdf

Version: 2024-02-01

| 33 | 913 | 567281 15 | 477307 29 |
|---|---|---|---|
| papers | citations | h-index | g-index |

| 36 | 36 | 36 | 1027 |
|---|---|---|---|
| all docs | docs citations | times ranked | citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | LLF580, an FGF21 Analog, Reduces Triglycerides and Hepatic Fat in Obese Adults With Modest Hypertriglyceridemia. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e57-e70. | 3.6 | 29 |
| 2 | Evaluation of cardiac parameters and other safety outcomes of brolucizumab treatment in patients with neovascular ageâ€related macular degeneration. Pharmacology Research and Perspectives, 2022, 10, e00897. | 2.4 | 2 |
| 3 | Open innovation: A paradigm shift in pharma R&D?. Drug Discovery Today, 2022, 27, 2395-2405. | 6.4 | 17 |
| 4 | Vascular effects of serelaxin in patients with stable coronary artery disease: a randomized placebo-controlled trial. Cardiovascular Research, 2021, 117, 320-329. | 3.8 | 3 |
| 5 | The present and future of project management in pharmaceutical R&D. Drug Discovery Today, 2021, 26, 1-4. | 6.4 | 5 |
| 6 | Big Techs and startups in pharmaceutical R&D â€“ A 2020 perspective on artificial intelligence. Drug Discovery Today, 2021, 26, 2226-2231. | 6.4 | 8 |
| 7 | Translational precision medicine: an industry perspective. Journal of Translational Medicine, 2021, 19, 245. | 4.4 | 51 |
| 8 | Licogliflozin versus placebo in women with polycystic ovary syndrome: A randomized, doubleâ€blind, phase 2 trial. Diabetes, Obesity and Metabolism, 2021, 23, 2595-2599. | 4.4 | 27 |
| 9 | Systematic risk identification and assessment using a new risk map in pharmaceutical R&D. Drug Discovery Today, 2021, 26, 2786-2793. | 6.4 | 8 |
| 10 | R&D efficiency of leading pharmaceutical companies â€“ A 20-year analysis. Drug Discovery Today, 2021, 26, 1784-1789. | 6.4 | 25 |
| 11 | A framework to guide dose & regimen strategy for clinical drug development. CPT: Pharmacometrics and Systems Pharmacology, 2021, 10, 1276-1280. | 2.5 | 5 |
| 12 | The upside of being a digital pharma player. Drug Discovery Today, 2020, 25, 1569-1574. | 6.4 | 33 |
| 13 | Investigation and Management of Stool Frequency and Consistency Associated With SGLT1 Inhibition by Reducing Dietary Carbohydrate: A Randomized Trial. Clinical Pharmacology and Therapeutics, 2020, 108, 995-1002. | 4.7 | 3 |
| 14 | The Art of Virtualizing Pharma R&D. Drug Discovery Today, 2019, 24, 2105-2107. | 6.4 | 8 |
| 15 | Developing Drugs for Heart Failure With Reduced Ejection Fraction: What Have We Learned From Clinical Trials?. Clinical Pharmacology and Therapeutics, 2018, 103, 802-814. | 4.7 | 6 |
| 16 | Pharmacodynamic interaction between intravenous nitroglycerin and oral sacubitril/valsartan (LCZ696) in healthy subjects. European Journal of Clinical Pharmacology, 2018, 74, 1121-1130. | 1.9 | 1 |
| 17 | Open innovation and external sources of innovation. An opportunity to fuel the R&D pipeline and enhance decision making?. Journal of Translational Medicine, 2018, 16, 119. | 4.4 | 36 |
| 18 | Pharmacokinetics, Safety and Tolerability of Sacubitril/Valsartan (LCZ696) After Single-Dose Administration in Healthy Chinese Subjects. European Journal of Drug Metabolism and Pharmacokinetics, 2017, 42, 109-116. | 1.6 | 19 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Effects of Sacubitril/Valsartan (LCZ696) on Natriuresis, Diuresis, Blood Pressures, and NT-proBNP in Salt-Sensitive Hypertension. Hypertension, 2017, 69, 32-41. | 2.7 | 98 |
| 20 | Introduction to the Book. , 2016, , 1-9. | | 0 |
| 21 | Changing R&D models in research-based pharmaceutical companies. Journal of Translational Medicine, 2016, 14, 105. | 4.4 | 231 |
| 22 | The effect of LCZ696 (sacubitril/valsartan) on amyloidâ€î² concentrations in cerebrospinal fluid in healthy subjects. British Journal of Clinical Pharmacology, 2016, 81, 878-890. | 2.4 | 89 |
| 23 | Effect of Steady-State Enoxacin on Single-Dose Pharmacokinetics of Roflumilast and Roflumilast N-Oxide. Journal of Clinical Pharmacology, 2011, 51, 586-593. | 2.0 | 17 |
| 24 | Use of Population Pharmacokinetic Modeling and Monte Carlo Simulation To Describe the Pharmacodynamic Profile of Cefditoren in Plasma and Epithelial Lining Fluid. Antimicrobial Agents and Chemotherapy, 2008, 52, 1945-1951. | 3.2 | 23 |
| 25 | Anticoagulant and anti-platelet effects are maintained following coadministration of otamixaban, a direct factor Xa inhibitor, and acetylsalicylic acid. Thrombosis and Haemostasis, 2006, 95, 224-228. | 3.4 | 10 |
| 26 | Pharmacokinetics of Otamixaban, a Direct Factor Xa Inhibitor, in Healthy Male Subjects: Pharmacokinetic Model Development for Phase 2/3 Simulation of Exposure. Journal of Clinical Pharmacology, 2006, 46, 37-44. | 2.0 | 29 |
| 27 | Direct and rapid inhibition of factor Xa by otamixaban: A pharmacokinetic and pharmacodynamic investigation in patients with coronary artery disease. Clinical Pharmacology and Therapeutics, 2006, 80, 691-702. | 4.7 | 24 |
| 28 | Pharmacokinetic/Pharmacodynamic Relationships for Otamixaban, a Direct Factor Xa Inhibitor, in Healthy Subjects. Journal of Clinical Pharmacology, 2006, 46, 45-51. | 2.0 | 9 |
| 29 | Anticoagulant and anti-platelet effects are maintained following coadministration of otamixaban, a direct factor Xa inhibitor, with tirofiban in healthy volunteers. Thrombosis and Haemostasis, 2005, 93, 794-795. | 3.4 | 7 |
| 30 | Comparison of the Initial Hemodynamic Effects of Immediate-Release versus Sustained-Release Isosorbide-5-Mononitrate following Single Oral Doses. Journal of Clinical Pharmacology, 2000, 40, 168-176. | 2.0 | 1 |
| 31 | Comparison of the efficacy and safety of losartan (50â€“100 mg) with the Tâ€type calcium channel blocker mibefradil (50â€“100 mg) in mild to moderate hypertension. Fundamental and Clinical Pharmacology, 2000, 14, 31-41. | 1.9 | 7 |
| 32 | Role of Renal Nerves in the Stimulation of the Renin System by Reduced Renal Arterial Pressure. Hypertension, 1999, 34, 1101-1105. | 2.7 | 38 |
| 33 | T-type and L-type calcium channel blockers exert opposite effects on renin secretion and renin gene expression in conscious rats. British Journal of Pharmacology, 1998, 124, 579-585. | 5.4 | 36 |